ANDA 206536, held by Zydus Pharms. Atorvastatin Calcium.
As of Nov 16, 2026, ANDA 206536 (Atorvastatin Calcium), held by Zydus Pharms, was first approved by FDA on Nov 20, 2018, with 7 approved supplements and 0 published complete response letters.
Atorvastatin calcium tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 20, 2018 | Original application | Approved | None posted |
| Atorvastatin CalciumEQ 10MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 20MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 40MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Atorvastatin CalciumEQ 80MG BASE · tablet;oral | Atorvastatin Calcium | Rx |
| Jul 10, 2024 | Supplement 18Labeling · Standard review | Approved | None posted |
| May 12, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Feb 24, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Feb 24, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 24, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 24, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 18, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 20, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters